Wearable Injectors Market | The key players in the global Wearable Injectors Market are Amgen , Medtronic , Insulet Corporation , Tandem Diabetes Care , United Therapeutics Corporation , Valeritas and SteadyMed Therapeutics .

According to the new market research report "Wearable Injectors Market by Type (On-Body and Off-Body injectors (Infusion Pump Devices)), Therapy (Immuno-oncology, Diabetes, Cardiovascular diseases, Parkinsons disease, Thalassemia, Primary Immunodeficiency Disease) - Global Forecast to 2023", published by MarketsandMarkets™, the global Wearable Injectors Market is projected to reach USD 9.41 billion by 2023 from USD 5.57 billion in 2018, at a CAGR of 11.1% during the forecast period (2018-2023).

Don't miss out on business opportunities in Wearable Injectors Market. Speak to Our Analyst and gain crucial industry insights that will help your business grow: https://www.marketsandmarkets.com/speaktoanalyst.asp?id=100771004&utm_source=OpenPR&utm_medium=Paid

The key factors driving the growth of this market are the growing prevalence of chronic diseases (such as cancer, diabetes, and cardiovascular diseases), favorable reimbursement scenario in major markets, and technological advancements in injector devices.

By type, the on-body injectors segment is expected to account for the largest market share in 2018
On the basis of type, the Wearable Injectors Market is segmented into on-body and off-body injectors. The on-body injectors segment is expected to account for the larger market share in 2018, while the off-body injectors segment is projected to witness the highest growth rate during the forecast period. The drawbacks associated with on-body wearable injectors, such as painful removal, skin sensitivity issues and irritation, and adhesive fitting issues have resulted in the increased adoption of off-body injectors.

Browse and in-depth TOC on "Wearable Injectors Market"
46 - Tables
30 - Figures
104 - Pages

View more detailed TOC @ https://www.marketsandmarkets.com/Market-Reports/wearable-injector-market-100771004.html?utm_source=OpenPR&utm_medium=Paid

By therapy, the immune-oncology segment is expected to account for the largest market share in 2018
On the basis of therapy, the Wearable Injectors Market is segmented into immuno-oncology, diabetes, cardiovascular diseases, and other therapies (Parkinson's disease, thalassemia, and primary immunodeficiency disorders). In 2018, the immune-oncology segment is expected to account for the largest share of the Wearable Injectors Market. This can be attributed to the high prevalence of cancer across the globe.

North America to dominate the market in 2018
In 2018, North America is expected to account for the largest share of the Wearable Injectors Market, followed by Europe. Factors such as availability of technologically advanced wearable injector systems for various therapeutic areas such as cancer, diabetes, and cardiovascular diseases; the presence of major market players in the region; and a favorable reimbursement scenario in the US and Canada are contributing to the large share of North America.

Request for Free Sample Report @
https://www.marketsandmarkets.com/requestsampleNew.asp?id=100771004&utm_source=OpenPR&utm_medium=Paid

The key players in the global Wearable Injectors Market are Amgen (US), Medtronic (Ireland), Insulet Corporation (US), Tandem Diabetes Care (US), United Therapeutics Corporation (US), Valeritas (US), and SteadyMed Therapeutics (US). The other prominent players in this market are Ypsomed (Switzerland), Becton, Dickinson and Company (US), Enable Injections (US), Sensile Medicals (Switzerland), and Bespak (UK).

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/wearable-injector-market.asp
Visit Our Website: https://www.marketsandmarkets.com

About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments.
MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

This release was published on openPR.